PortfoliosLab logoPortfoliosLab logo
KRYS vs. CAMT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KRYS vs. CAMT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and Camtek Ltd (CAMT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KRYS achieves a 22.42% return, which is significantly lower than CAMT's 72.50% return.


KRYS

1D
2.94%
1M
5.18%
YTD
22.42%
6M
38.79%
1Y
130.56%
3Y*
34.44%
5Y*
37.14%
10Y*

CAMT

1D
-2.17%
1M
0.41%
YTD
72.50%
6M
56.89%
1Y
169.62%
3Y*
86.90%
5Y*
37.88%
10Y*
58.39%
*Multi-year figures are annualized to reflect compound growth (CAGR)

KRYS vs. CAMT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
KRYS
Krystal Biotech, Inc.
22.42%57.37%26.28%56.60%13.25%16.58%8.34%166.51%97.53%-1.13%
CAMT
Camtek Ltd
72.50%31.66%18.33%215.94%-52.30%110.13%102.31%63.19%20.41%18.60%

Correlation

The correlation between KRYS and CAMT is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.14

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.26

Correlation (All Time)
Calculated using the full available price history since Sep 21, 2017

0.25

The correlation between KRYS and CAMT shifts across timeframes, from 0.14 (1 year) to 0.26 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

KRYS:

$9.21B

CAMT:

$9.44B

EPS

KRYS:

$7.50

CAMT:

$0.98

PE Ratio

KRYS:

40.25

CAMT:

187.55

PEG Ratio

KRYS:

0.10

CAMT:

38.22

PS Ratio

KRYS:

21.71

CAMT:

18.06

PB Ratio

KRYS:

7.21

CAMT:

13.83

Total Revenue (TTM)

KRYS:

$417.30M

CAMT:

$499.09M

Gross Profit (TTM)

KRYS:

$387.24M

CAMT:

$250.68M

EBITDA (TTM)

KRYS:

$185.45M

CAMT:

$122.77M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KRYS vs. CAMT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS
KRYS Risk / Return Rank: 9494
Overall Rank
KRYS Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
KRYS Sortino Ratio Rank: 9393
Sortino Ratio Rank
KRYS Omega Ratio Rank: 9292
Omega Ratio Rank
KRYS Calmar Ratio Rank: 9696
Calmar Ratio Rank
KRYS Martin Ratio Rank: 9696
Martin Ratio Rank

CAMT
CAMT Risk / Return Rank: 9090
Overall Rank
CAMT Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
CAMT Sortino Ratio Rank: 8787
Sortino Ratio Rank
CAMT Omega Ratio Rank: 8686
Omega Ratio Rank
CAMT Calmar Ratio Rank: 9494
Calmar Ratio Rank
CAMT Martin Ratio Rank: 9393
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KRYS vs. CAMT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Camtek Ltd (CAMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


KRYSCAMTDifference

Sharpe ratio

Return per unit of total volatility

3.38

2.74

+0.64

Sortino ratio

Return per unit of downside risk

3.62

2.96

+0.66

Omega ratio

Gain probability vs. loss probability

1.50

1.37

+0.12

Calmar ratio

Return relative to maximum drawdown

8.24

6.31

+1.93

Martin ratio

Return relative to average drawdown

21.37

15.89

+5.47

KRYS vs. CAMT - Sharpe Ratio Comparison

The current KRYS Sharpe Ratio is 3.38, which is comparable to the CAMT Sharpe Ratio of 2.74. The chart below compares the historical Sharpe Ratios of KRYS and CAMT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


KRYSCAMTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.38

2.74

+0.64

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.49

0.69

-0.20

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

1.13

Sharpe Ratio (All Time)

Calculated using the full available price history

0.63

0.21

+0.42

Drawdowns

KRYS vs. CAMT - Drawdown Comparison

The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum CAMT drawdown of -97.71%. Use the drawdown chart below to compare losses from any high point for KRYS and CAMT.


Loading charts...

Drawdown Indicators


KRYSCAMTDifference

Max Drawdown

Largest peak-to-trough decline

-53.42%

-97.71%

+44.29%

Max Drawdown (1Y)

Largest decline over 1 year

-15.94%

-27.07%

+11.13%

Max Drawdown (3Y)

Largest decline over 3 years

-42.26%

-63.16%

+20.90%

Max Drawdown (5Y)

Largest decline over 5 years

-44.55%

-63.16%

+18.61%

Max Drawdown (10Y)

Largest decline over 10 years

-63.16%

Current Drawdown

Current decline from peak

-4.58%

-11.57%

+6.99%

Average Drawdown

Average peak-to-trough decline

-16.22%

-55.75%

+39.53%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.13%

10.72%

-4.59%

Volatility

KRYS vs. CAMT - Volatility Comparison

The current volatility for Krystal Biotech, Inc. (KRYS) is 10.26%, while Camtek Ltd (CAMT) has a volatility of 29.35%. This indicates that KRYS experiences smaller price fluctuations and is considered to be less risky than CAMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KRYSCAMTDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.26%

29.35%

-19.09%

Volatility (6M)

Calculated over the trailing 6-month period

27.20%

48.52%

-21.32%

Volatility (1Y)

Calculated over the trailing 1-year period

39.04%

62.21%

-23.17%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

76.43%

55.44%

+20.99%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

74.23%

51.79%

+22.44%

Dividends

KRYS vs. CAMT - Dividend Comparison

Neither KRYS nor CAMT has paid dividends to shareholders.


PositionTTM202520242023202220212020201920182017
CAMT
Camtek Ltd
0.00%0.00%1.65%0.00%0.00%0.00%0.00%1.57%2.07%2.45%
KRYS
Krystal Biotech, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

KRYS vs. CAMT - Financials Comparison

This section allows you to compare key financial metrics between Krystal Biotech, Inc. and Camtek Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00M20222023202420252026
116.36M
121.66M
(KRYS) Total Revenue
(CAMT) Total Revenue
Values in USD except per share items

KRYS vs. CAMT - Profitability Comparison

The chart below illustrates the profitability comparison between Krystal Biotech, Inc. and Camtek Ltd over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
94.6%
50.1%
Portfolio components
KRYS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a gross profit of 110.03M and revenue of 116.36M. Therefore, the gross margin over that period was 94.6%.

CAMT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Camtek Ltd reported a gross profit of 60.93M and revenue of 121.66M. Therefore, the gross margin over that period was 50.1%.

KRYS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported an operating income of 53.69M and revenue of 116.36M, resulting in an operating margin of 46.1%.

CAMT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Camtek Ltd reported an operating income of 27.27M and revenue of 121.66M, resulting in an operating margin of 22.4%.

KRYS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a net income of 55.93M and revenue of 116.36M, resulting in a net margin of 48.1%.

CAMT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Camtek Ltd reported a net income of 31.65M and revenue of 121.66M, resulting in a net margin of 26.0%.


Frequently Asked Questions


KRYS and CAMT have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CAMT has higher volatility (29.35%) compared to KRYS (10.26%). In terms of maximum drawdown, KRYS dropped -53.42% vs CAMT's -97.71%.

KRYS currently has the higher Sharpe Ratio (3.38 vs 2.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KRYS and CAMT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer